APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hepatic Encephalopathy Drug Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hepatic Encephalopathy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hepatic Encephalopathy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hepatic Encephalopathy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hepatic Encephalopathy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hepatic Encephalopathy Drug include Umecrine Cognition AB, Spherium Biomed S.L., Rebiotix Inc., Ocera Therapeutics, Inc., KannaLife Sciences, Inc., Horizon Pharma Plc, Cosmo Pharmaceuticals S.p.A and Alfa Wassermann S.p.A, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hepatic Encephalopathy Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hepatic Encephalopathy Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Hepatic Encephalopathy Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatic Encephalopathy Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hepatic Encephalopathy Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hepatic Encephalopathy Drug sales, projected growth trends, production technology, application and end-user industry.

Hepatic Encephalopathy Drug Segment by Company

Umecrine Cognition AB

Spherium Biomed S.L.

Rebiotix Inc.

Ocera Therapeutics, Inc.

KannaLife Sciences, Inc.

Horizon Pharma Plc

Cosmo Pharmaceuticals S.p.A

Alfa Wassermann S.p.A

Hepatic Encephalopathy Drug Segment by Type

GR-3027

KLS-13019

RBX-2660

SYNB-1020

Others

Hepatic Encephalopathy Drug Segment by Application

Clinic

Hospital

Others

Hepatic Encephalopathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hepatic Encephalopathy Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hepatic Encephalopathy Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatic Encephalopathy Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. GR-3027 Major Manufacturers Table 3. KLS-13019 Major Manufacturers Table 4. RBX-2660 Major Manufacturers Table 5. SYNB-1020 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Manufacturers Table 9. Hospital Major Manufacturers Table 10. Others Major Manufacturers Table 11. Hepatic Encephalopathy Drug Industry Trends Table 12. Hepatic Encephalopathy Drug Industry Drivers Table 13. Hepatic Encephalopathy Drug Industry Opportunities and Challenges Table 14. Hepatic Encephalopathy Drug Industry Restraints Table 15. Global Hepatic Encephalopathy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Hepatic Encephalopathy Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Hepatic Encephalopathy Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2021-2026) Table 19. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2027-2032) Table 20. Global Hepatic Encephalopathy Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 21. Global Hepatic Encephalopathy Drug Sales by Region (2021-2026) & (W Units) Table 22. Global Hepatic Encephalopathy Drug Sales by Region (2027-2032) & (W Units) Table 23. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2021-2026) Table 24. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2027-2032) Table 25. Global Hepatic Encephalopathy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Hepatic Encephalopathy Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Hepatic Encephalopathy Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Hepatic Encephalopathy Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Hepatic Encephalopathy Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Hepatic Encephalopathy Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Hepatic Encephalopathy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Hepatic Encephalopathy Drug Manufacturers, Product Type & Application Table 33. Global Hepatic Encephalopathy Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Hepatic Encephalopathy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Hepatic Encephalopathy Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2026) Table 40. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2027-2032) Table 41. Global Hepatic Encephalopathy Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 42. Global Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 43. Global Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 44. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2026) Table 45. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2027-2032) Table 46. Global Hepatic Encephalopathy Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Hepatic Encephalopathy Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Hepatic Encephalopathy Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2026) Table 52. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2027-2032) Table 53. Global Hepatic Encephalopathy Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 54. Global Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 55. Global Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 56. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2026) Table 57. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2027-2032) Table 58. Global Hepatic Encephalopathy Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Hepatic Encephalopathy Drug Price by Application (2027-2032) & (US$/Unit) Table 60. Umecrine Cognition AB Company Information Table 61. Umecrine Cognition AB Business Overview Table 62. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio Table 64. Umecrine Cognition AB Recent Development Table 65. Spherium Biomed S.L. Company Information Table 66. Spherium Biomed S.L. Business Overview Table 67. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio Table 69. Spherium Biomed S.L. Recent Development Table 70. Rebiotix Inc. Company Information Table 71. Rebiotix Inc. Business Overview Table 72. Rebiotix Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio Table 74. Rebiotix Inc. Recent Development Table 75. Ocera Therapeutics, Inc. Company Information Table 76. Ocera Therapeutics, Inc. Business Overview Table 77. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 79. Ocera Therapeutics, Inc. Recent Development Table 80. KannaLife Sciences, Inc. Company Information Table 81. KannaLife Sciences, Inc. Business Overview Table 82. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio Table 84. KannaLife Sciences, Inc. Recent Development Table 85. Horizon Pharma Plc Company Information Table 86. Horizon Pharma Plc Business Overview Table 87. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio Table 89. Horizon Pharma Plc Recent Development Table 90. Cosmo Pharmaceuticals S.p.A Company Information Table 91. Cosmo Pharmaceuticals S.p.A Business Overview Table 92. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 94. Cosmo Pharmaceuticals S.p.A Recent Development Table 95. Alfa Wassermann S.p.A Company Information Table 96. Alfa Wassermann S.p.A Business Overview Table 97. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio Table 99. Alfa Wassermann S.p.A Recent Development Table 100. North America Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 103. North America Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 104. North America Hepatic Encephalopathy Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 105. North America Hepatic Encephalopathy Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 106. North America Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. North America Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. North America Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 109. North America Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 110. North America Hepatic Encephalopathy Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 111. North America Hepatic Encephalopathy Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 112. North America Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 114. North America Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 115. North America Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 116. North America Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 117. North America Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 118. North America Hepatic Encephalopathy Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 119. North America Hepatic Encephalopathy Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 120. United States Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 121. Canada Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 122. Europe Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 125. Europe Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 126. Europe Hepatic Encephalopathy Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 127. Europe Hepatic Encephalopathy Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 128. Europe Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 129. Europe Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 130. Europe Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 131. Europe Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 132. Europe Hepatic Encephalopathy Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 133. Europe Hepatic Encephalopathy Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 134. Europe Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Europe Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. Europe Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. Europe Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 138. Europe Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 139. Europe Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 140. Europe Hepatic Encephalopathy Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 141. Europe Hepatic Encephalopathy Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 142. Germany Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 143. France Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 144. U.K. Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 145. Italy Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 146. Netherlands Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 147. Nordic Countries Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 148. China Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. China Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. China Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 151. China Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 152. China Hepatic Encephalopathy Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 153. China Hepatic Encephalopathy Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 154. China Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 155. China Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 156. China Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 157. China Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 158. China Hepatic Encephalopathy Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 159. China Hepatic Encephalopathy Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 160. Asia Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 163. Asia Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 164. Asia Hepatic Encephalopathy Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 165. Asia Hepatic Encephalopathy Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 166. Asia Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 169. Asia Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 170. Asia Hepatic Encephalopathy Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 171. Asia Hepatic Encephalopathy Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 172. Asia Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Asia Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Asia Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Asia Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 176. Asia Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 177. Asia Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 178. Asia Hepatic Encephalopathy Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 179. Asia Hepatic Encephalopathy Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 180. Japan Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 181. South Korea Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 182. India Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 183. Australia Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 184. China Taiwan Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 185. Southeast Asia Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 186. SAMEA Hepatic Encephalopathy Drug Revenue by Type (2021-2026) & (US$ Million) Table 187. SAMEA Hepatic Encephalopathy Drug Revenue by Type (2027-2032) & (US$ Million) Table 188. SAMEA Hepatic Encephalopathy Drug Sales by Type (2021-2026) & (W Units) Table 189. SAMEA Hepatic Encephalopathy Drug Sales by Type (2027-2032) & (W Units) Table 190. SAMEA Hepatic Encephalopathy Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 191. SAMEA Hepatic Encephalopathy Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 192. SAMEA Hepatic Encephalopathy Drug Revenue by Application (2021-2026) & (US$ Million) Table 193. SAMEA Hepatic Encephalopathy Drug Revenue by Application (2027-2032) & (US$ Million) Table 194. SAMEA Hepatic Encephalopathy Drug Sales by Application (2021-2026) & (W Units) Table 195. SAMEA Hepatic Encephalopathy Drug Sales by Application (2027-2032) & (W Units) Table 196. SAMEA Hepatic Encephalopathy Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 197. SAMEA Hepatic Encephalopathy Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 198. SAMEA Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. SAMEA Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. SAMEA Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. SAMEA Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 202. SAMEA Hepatic Encephalopathy Drug Sales by Country (2021-2026) & (W Units) Table 203. SAMEA Hepatic Encephalopathy Drug Sales by Country (2027-2032) & (W Units) Table 204. SAMEA Hepatic Encephalopathy Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 205. SAMEA Hepatic Encephalopathy Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 206. Brazil Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 207. Argentina Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 208. Chile Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 209. Colombia Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 210. Peru Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 211. Saudi Arabia Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 212. Israel Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 213. UAE Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 214. Turkey Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 215. Iran Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 216. Egypt Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Hepatic Encephalopathy Drug Distributors List Table 220. Hepatic Encephalopathy Drug Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drug Image Figure 2. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. GR-3027 Image Figure 5. KLS-13019 Image Figure 6. RBX-2660 Image Figure 7. SYNB-1020 Image Figure 8. Others Image Figure 9. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Hepatic Encephalopathy Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Hepatic Encephalopathy Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Hepatic Encephalopathy Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Hepatic Encephalopathy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Hepatic Encephalopathy Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Hepatic Encephalopathy Drug Sales (2021-2032) & (W Units) Figure 20. Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 21. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Hepatic Encephalopathy Drug Sales YoY (2021-2032) & (W Units) Figure 23. Europe Hepatic Encephalopathy Drug Sales YoY (2021-2032) & (W Units) Figure 24. China Hepatic Encephalopathy Drug Sales YoY (2021-2032) & (W Units) Figure 25. Asia (Excluding China) Hepatic Encephalopathy Drug Sales YoY (2021-2032) & (W Units) Figure 26. South America, Middle East and Africa Hepatic Encephalopathy Drug Sales YoY (2021-2032) & (W Units) Figure 27. Global Hepatic Encephalopathy Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Hepatic Encephalopathy Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Hepatic Encephalopathy Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Hepatic Encephalopathy Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Hepatic Encephalopathy Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 34. Global Hepatic Encephalopathy Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2032) Figure 36. Global Hepatic Encephalopathy Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Hepatic Encephalopathy Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Hepatic Encephalopathy Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 40. Global Hepatic Encephalopathy Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2032) Figure 42. North America Hepatic Encephalopathy Drug Revenue Share by Type (2021-2032) Figure 43. North America Hepatic Encephalopathy Drug Sales Share by Type (2021-2032) Figure 44. North America Hepatic Encephalopathy Drug Revenue Share by Application (2021-2032) Figure 45. North America Hepatic Encephalopathy Drug Sales Share by Application (2021-2032) Figure 46. North America Hepatic Encephalopathy Drug Revenue Share by Country (2021-2032) Figure 47. North America Hepatic Encephalopathy Drug Sales Share by Country (2021-2032) Figure 48. Europe Hepatic Encephalopathy Drug Revenue Share by Type (2021-2032) Figure 49. Europe Hepatic Encephalopathy Drug Sales Share by Type (2021-2032) Figure 50. Europe Hepatic Encephalopathy Drug Revenue Share by Application (2021-2032) Figure 51. Europe Hepatic Encephalopathy Drug Sales Share by Application (2021-2032) Figure 52. Europe Hepatic Encephalopathy Drug Revenue Share by Country (2021-2032) Figure 53. Europe Hepatic Encephalopathy Drug Sales Share by Country (2021-2032) Figure 54. China Hepatic Encephalopathy Drug Revenue Share by Type (2021-2032) Figure 55. China Hepatic Encephalopathy Drug Sales Share by Type (2021-2032) Figure 56. China Hepatic Encephalopathy Drug Revenue Share by Application (2021-2032) Figure 57. China Hepatic Encephalopathy Drug Sales Share by Application (2021-2032) Figure 58. Asia Hepatic Encephalopathy Drug Revenue Share by Type (2021-2032) Figure 59. Asia Hepatic Encephalopathy Drug Sales Share by Type (2021-2032) Figure 60. Asia Hepatic Encephalopathy Drug Revenue Share by Application (2021-2032) Figure 61. Asia Hepatic Encephalopathy Drug Sales Share by Application (2021-2032) Figure 62. Asia Hepatic Encephalopathy Drug Revenue Share by Country (2021-2032) Figure 63. Asia Hepatic Encephalopathy Drug Sales Share by Country (2021-2032) Figure 64. SAMEA Hepatic Encephalopathy Drug Revenue Share by Type (2021-2032) Figure 65. SAMEA Hepatic Encephalopathy Drug Sales Share by Type (2021-2032) Figure 66. SAMEA Hepatic Encephalopathy Drug Revenue Share by Application (2021-2032) Figure 67. SAMEA Hepatic Encephalopathy Drug Sales Share by Application (2021-2032) Figure 68. SAMEA Hepatic Encephalopathy Drug Revenue Share by Country (2021-2032) Figure 69. SAMEA Hepatic Encephalopathy Drug Sales Share by Country (2021-2032) Figure 70. Hepatic Encephalopathy Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Hepatic Encephalopathy Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • GR-3027
  • KLS-13019
  • RBX-2660
  • SYNB-1020
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Umecrine Cognition AB
  • Spherium Biomed S.L.
  • Rebiotix Inc.
  • Ocera Therapeutics, Inc.
  • KannaLife Sciences, Inc.
  • Horizon Pharma Plc
  • Cosmo Pharmaceuticals S.p.A
  • Alfa Wassermann S.p.A

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hepatic Encephalopathy Drug Market by Type
  3. 1.2.1 Global Hepatic Encephalopathy Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 GR-3027
  5. 1.2.3 KLS-13019
  6. 1.2.4 RBX-2660
  7. 1.2.5 SYNB-1020
  8. 1.2.6 Others
  9. 1.3 Hepatic Encephalopathy Drug Market by Application
  10. 1.3.1 Global Hepatic Encephalopathy Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Hepatic Encephalopathy Drug Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drug Industry Trends
  2. 2.2 Hepatic Encephalopathy Drug Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drug Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hepatic Encephalopathy Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hepatic Encephalopathy Drug Revenue by Region
  3. 3.2.1 Global Hepatic Encephalopathy Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hepatic Encephalopathy Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Hepatic Encephalopathy Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hepatic Encephalopathy Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hepatic Encephalopathy Drug Sales by Region
  9. 3.4.1 Global Hepatic Encephalopathy Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hepatic Encephalopathy Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Hepatic Encephalopathy Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Hepatic Encephalopathy Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hepatic Encephalopathy Drug Revenue by Manufacturers
  2. 4.1.1 Global Hepatic Encephalopathy Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hepatic Encephalopathy Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hepatic Encephalopathy Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hepatic Encephalopathy Drug Sales by Manufacturers
  6. 4.2.1 Global Hepatic Encephalopathy Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hepatic Encephalopathy Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hepatic Encephalopathy Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hepatic Encephalopathy Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hepatic Encephalopathy Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hepatic Encephalopathy Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hepatic Encephalopathy Drug Manufacturers, Product Type & Application
  13. 4.7 Global Hepatic Encephalopathy Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hepatic Encephalopathy Drug Market CR5 and HHI
  16. 4.8.2 2025 Hepatic Encephalopathy Drug Tier 1, Tier 2, and Tier 3
5 Hepatic Encephalopathy Drug Market by Type
  1. 5.1 Global Hepatic Encephalopathy Drug Revenue by Type
  2. 5.1.1 Global Hepatic Encephalopathy Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hepatic Encephalopathy Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hepatic Encephalopathy Drug Sales by Type
  6. 5.2.1 Global Hepatic Encephalopathy Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drug Price by Type
6 Hepatic Encephalopathy Drug Market by Application
  1. 6.1 Global Hepatic Encephalopathy Drug Revenue by Application
  2. 6.1.1 Global Hepatic Encephalopathy Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hepatic Encephalopathy Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hepatic Encephalopathy Drug Sales by Application
  6. 6.2.1 Global Hepatic Encephalopathy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hepatic Encephalopathy Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hepatic Encephalopathy Drug Price by Application
7 Company Profiles
  1. 7.1 Umecrine Cognition AB
  2. 7.1.1 Umecrine Cognition AB Company Information
  3. 7.1.2 Umecrine Cognition AB Business Overview
  4. 7.1.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio
  6. 7.1.5 Umecrine Cognition AB Recent Developments
  7. 7.2 Spherium Biomed S.L.
  8. 7.2.1 Spherium Biomed S.L. Company Information
  9. 7.2.2 Spherium Biomed S.L. Business Overview
  10. 7.2.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio
  12. 7.2.5 Spherium Biomed S.L. Recent Developments
  13. 7.3 Rebiotix Inc.
  14. 7.3.1 Rebiotix Inc. Company Information
  15. 7.3.2 Rebiotix Inc. Business Overview
  16. 7.3.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio
  18. 7.3.5 Rebiotix Inc. Recent Developments
  19. 7.4 Ocera Therapeutics, Inc.
  20. 7.4.1 Ocera Therapeutics, Inc. Company Information
  21. 7.4.2 Ocera Therapeutics, Inc. Business Overview
  22. 7.4.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio
  24. 7.4.5 Ocera Therapeutics, Inc. Recent Developments
  25. 7.5 KannaLife Sciences, Inc.
  26. 7.5.1 KannaLife Sciences, Inc. Company Information
  27. 7.5.2 KannaLife Sciences, Inc. Business Overview
  28. 7.5.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio
  30. 7.5.5 KannaLife Sciences, Inc. Recent Developments
  31. 7.6 Horizon Pharma Plc
  32. 7.6.1 Horizon Pharma Plc Company Information
  33. 7.6.2 Horizon Pharma Plc Business Overview
  34. 7.6.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio
  36. 7.6.5 Horizon Pharma Plc Recent Developments
  37. 7.7 Cosmo Pharmaceuticals S.p.A
  38. 7.7.1 Cosmo Pharmaceuticals S.p.A Company Information
  39. 7.7.2 Cosmo Pharmaceuticals S.p.A Business Overview
  40. 7.7.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio
  42. 7.7.5 Cosmo Pharmaceuticals S.p.A Recent Developments
  43. 7.8 Alfa Wassermann S.p.A
  44. 7.8.1 Alfa Wassermann S.p.A Company Information
  45. 7.8.2 Alfa Wassermann S.p.A Business Overview
  46. 7.8.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio
  48. 7.8.5 Alfa Wassermann S.p.A Recent Developments
8 North America
  1. 8.1 North America Hepatic Encephalopathy Drug Market Size by Type
  2. 8.1.1 North America Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Hepatic Encephalopathy Drug Price by Type (2021-2032)
  5. 8.2 North America Hepatic Encephalopathy Drug Market Size by Application
  6. 8.2.1 North America Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Hepatic Encephalopathy Drug Price by Application (2021-2032)
  9. 8.3 North America Hepatic Encephalopathy Drug Market Size by Country
  10. 8.3.1 North America Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hepatic Encephalopathy Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Hepatic Encephalopathy Drug Market Size by Type
  2. 9.1.1 Europe Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Hepatic Encephalopathy Drug Price by Type (2021-2032)
  5. 9.2 Europe Hepatic Encephalopathy Drug Market Size by Application
  6. 9.2.1 Europe Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Hepatic Encephalopathy Drug Price by Application (2021-2032)
  9. 9.3 Europe Hepatic Encephalopathy Drug Market Size by Country
  10. 9.3.1 Europe Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hepatic Encephalopathy Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Hepatic Encephalopathy Drug Market Size by Type
  2. 10.1.1 China Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  4. 10.1.3 China Hepatic Encephalopathy Drug Price by Type (2021-2032)
  5. 10.2 China Hepatic Encephalopathy Drug Market Size by Application
  6. 10.2.1 China Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 10.2.3 China Hepatic Encephalopathy Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hepatic Encephalopathy Drug Market Size by Type
  2. 11.1.1 Asia Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Hepatic Encephalopathy Drug Price by Type (2021-2032)
  5. 11.2 Asia Hepatic Encephalopathy Drug Market Size by Application
  6. 11.2.1 Asia Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Hepatic Encephalopathy Drug Price by Application (2021-2032)
  9. 11.3 Asia Hepatic Encephalopathy Drug Market Size by Country
  10. 11.3.1 Asia Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hepatic Encephalopathy Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hepatic Encephalopathy Drug Market Size by Type
  2. 12.1.1 SAMEA Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hepatic Encephalopathy Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hepatic Encephalopathy Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Hepatic Encephalopathy Drug Market Size by Application
  6. 12.2.1 SAMEA Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hepatic Encephalopathy Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hepatic Encephalopathy Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Hepatic Encephalopathy Drug Market Size by Country
  10. 12.3.1 SAMEA Hepatic Encephalopathy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hepatic Encephalopathy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hepatic Encephalopathy Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hepatic Encephalopathy Drug Value Chain Analysis
  2. 13.1.1 Hepatic Encephalopathy Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hepatic Encephalopathy Drug Production Mode & Process
  6. 13.2 Hepatic Encephalopathy Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hepatic Encephalopathy Drug Distributors
  9. 13.2.3 Hepatic Encephalopathy Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst